About Ico Therapeutics
iCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: OTCMKTS
- Symbol: ICOTF
- Previous Close: $0.03
- 50 Day Moving Average: $0.03
- 200 Day Moving Average: $0.04
- 52-Week Range: $0.02 - $0.07
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $2.53M
- Outstanding Shares: 84,457,000
- Beta: 2.57
- Return on Equity: -59.51%
- Return on Assets: -57.48%
Companies Related to Ico Therapeutics:
- Current Ratio: 18.36%
- Quick Ratio: 18.36%
Consensus Ratings for Ico Therapeutics (OTCMKTS:ICOTF) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Ico Therapeutics (OTCMKTS:ICOTF)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Ico Therapeutics (OTCMKTS:ICOTF)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Ico Therapeutics (OTCMKTS:ICOTF)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Ico Therapeutics (OTCMKTS:ICOTF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Ico Therapeutics (OTCMKTS:ICOTF)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Ico Therapeutics (OTCMKTS:ICOTF)
What is Ico Therapeutics' stock symbol?
Ico Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF."
How do I buy Ico Therapeutics stock?
Shares of Ico Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ico Therapeutics stock cost?
One share of Ico Therapeutics stock can currently be purchased for approximately $0.03.
Ico Therapeutics (OTCMKTS:ICOTF) Chart for Tuesday, February, 28, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart